Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Temozolomide in Newly Diagnosed High-Grade Glioma
NCT06413706Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of abemaciclib in glioma, sponsored by Eli Lilly and Company. Started Oct 2024; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06413706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413706.